Korro Bio, Inc. KRRO
Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026
Korro Bio, Inc. (KRRO) is a healthcare company listed in the US with a market value of about $187M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$106M, a net margin of -8214.5%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -30% a year, a 5-year average ROIC of -57%.
About Korro Bio
Korro Bio is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2019. Revenue went from $29M in 2019 to $6M in 2025, a decline of about 22.3% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 3582% over three years (dilution for shareholders). It spends 1026% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $6M | $2M | $0 | $0 | $14M | $37M | $29M | — | — |
| Net income | -$106M | -$117M | -$84M | -$81M | -$58M | -$85M | -$27M | -$19M | -$19M | -$20M |
| Free cash flow | -$64M | -$79M | -$78M | -$75M | -$59M | -$79M | -$52M | $33M | -$17M | -$16M |
| EPS (diluted) | $-5.94 | $-12.48 | $-9.37 | $-53.08 | $-227.42 | $-2.47 | $-0.82 | $-2.29 | $-12.53 | $-28.79 |
| Net margin | -8214.5% | -1834.5% | -3680.4% | — | — | -602.0% | -71.7% | -64.8% | — | — |
| ROIC | — | -101.4% | -35.4% | -32.9% | — | — | -11.2% | -12.2% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Korro Bio pay a dividend?
Not currently.
Is Korro Bio a good stock to buy?
We do not give buy or sell advice. Korro Bio scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.